NASDAQ:FLXN

Flexion Therapeutics Competitors

$8.12
-0.18 (-2.17 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.05
Now: $8.12
$8.41
50-Day Range
$8.30
MA: $10.41
$11.85
52-Week Range
$7.52
Now: $8.12
$14.39
Volume1.05 million shs
Average Volume770,949 shs
Market Capitalization$405.38 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64

Competitors

Flexion Therapeutics (NASDAQ:FLXN) Vs. HRMY, TVTX, ZNTL, GBIO, KRON, and QURE

Should you be buying FLXN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Flexion Therapeutics, including Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), Zentalis Pharmaceuticals (ZNTL), Generation Bio (GBIO), Kronos Bio (KRON), and uniQure (QURE).

Flexion Therapeutics (NASDAQ:FLXN) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Flexion Therapeutics and Harmony Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flexion Therapeutics$72.96 million5.56$-149,770,000.00($3.93)-2.07
Harmony BiosciencesN/AN/AN/AN/AN/A

Harmony Biosciences has lower revenue, but higher earnings than Flexion Therapeutics.

Profitability

This table compares Flexion Therapeutics and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Flexion Therapeutics-153.90%N/A-53.31%
Harmony BiosciencesN/AN/AN/A

Institutional and Insider Ownership

50.2% of Harmony Biosciences shares are held by institutional investors. 17.0% of Flexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Flexion Therapeutics and Harmony Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Flexion Therapeutics01913.00
Harmony Biosciences00303.00

Flexion Therapeutics currently has a consensus price target of $20.4545, suggesting a potential upside of 151.90%. Harmony Biosciences has a consensus price target of $51.6667, suggesting a potential upside of 82.44%. Given Flexion Therapeutics' higher possible upside, equities research analysts plainly believe Flexion Therapeutics is more favorable than Harmony Biosciences.

Summary

Flexion Therapeutics beats Harmony Biosciences on 5 of the 8 factors compared between the two stocks.

Travere Therapeutics (NASDAQ:TVTX) and Flexion Therapeutics (NASDAQ:FLXN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings for Travere Therapeutics and Flexion Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00403.00
Flexion Therapeutics01913.00

Travere Therapeutics currently has a consensus target price of $47.00, suggesting a potential upside of 83.52%. Flexion Therapeutics has a consensus target price of $20.4545, suggesting a potential upside of 151.90%. Given Flexion Therapeutics' higher possible upside, analysts plainly believe Flexion Therapeutics is more favorable than Travere Therapeutics.

Profitability

This table compares Travere Therapeutics and Flexion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
Flexion Therapeutics-153.90%N/A-53.31%

Risk and Volatility

Travere Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Flexion Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.

Valuation & Earnings

This table compares Travere Therapeutics and Flexion Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.83$-146,430,000.00($3.46)-7.40
Flexion Therapeutics$72.96 million5.56$-149,770,000.00($3.93)-2.07

Travere Therapeutics has higher revenue and earnings than Flexion Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Flexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Flexion Therapeutics (NASDAQ:FLXN) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Profitability

This table compares Flexion Therapeutics and Zentalis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Flexion Therapeutics-153.90%N/A-53.31%
Zentalis PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Flexion Therapeutics and Zentalis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Flexion Therapeutics01913.00
Zentalis Pharmaceuticals00703.00

Flexion Therapeutics currently has a consensus target price of $20.4545, indicating a potential upside of 151.90%. Zentalis Pharmaceuticals has a consensus target price of $54.2857, indicating a potential upside of 45.11%. Given Flexion Therapeutics' higher probable upside, equities research analysts clearly believe Flexion Therapeutics is more favorable than Zentalis Pharmaceuticals.

Valuation & Earnings

This table compares Flexion Therapeutics and Zentalis Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flexion Therapeutics$72.96 million5.56$-149,770,000.00($3.93)-2.07
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A

Zentalis Pharmaceuticals has lower revenue, but higher earnings than Flexion Therapeutics.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. 17.0% of Flexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Flexion Therapeutics beats Zentalis Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Flexion Therapeutics (NASDAQ:FLXN) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Flexion Therapeutics and Generation Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Flexion Therapeutics01913.00
Generation Bio00603.00

Flexion Therapeutics currently has a consensus target price of $20.4545, indicating a potential upside of 151.90%. Generation Bio has a consensus target price of $40.60, indicating a potential upside of 49.26%. Given Flexion Therapeutics' higher possible upside, analysts plainly believe Flexion Therapeutics is more favorable than Generation Bio.

Insider and Institutional Ownership

63.3% of Generation Bio shares are held by institutional investors. 17.0% of Flexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Flexion Therapeutics and Generation Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flexion Therapeutics$72.96 million5.56$-149,770,000.00($3.93)-2.07
Generation BioN/AN/AN/AN/AN/A

Generation Bio has lower revenue, but higher earnings than Flexion Therapeutics.

Profitability

This table compares Flexion Therapeutics and Generation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Flexion Therapeutics-153.90%N/A-53.31%
Generation BioN/AN/AN/A

Summary

Flexion Therapeutics beats Generation Bio on 5 of the 8 factors compared between the two stocks.

Kronos Bio (NASDAQ:KRON) and Flexion Therapeutics (NASDAQ:FLXN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Profitability

This table compares Kronos Bio and Flexion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kronos BioN/AN/AN/A
Flexion Therapeutics-153.90%N/A-53.31%

Valuation & Earnings

This table compares Kronos Bio and Flexion Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kronos BioN/AN/AN/AN/AN/A
Flexion Therapeutics$72.96 million5.56$-149,770,000.00($3.93)-2.07

Kronos Bio has higher earnings, but lower revenue than Flexion Therapeutics.

Analyst Recommendations

This is a summary of current ratings and price targets for Kronos Bio and Flexion Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kronos Bio00403.00
Flexion Therapeutics01913.00

Kronos Bio currently has a consensus price target of $43.6667, indicating a potential upside of 60.07%. Flexion Therapeutics has a consensus price target of $20.4545, indicating a potential upside of 151.90%. Given Flexion Therapeutics' higher probable upside, analysts plainly believe Flexion Therapeutics is more favorable than Kronos Bio.

Summary

Flexion Therapeutics beats Kronos Bio on 4 of the 6 factors compared between the two stocks.

Flexion Therapeutics (NASDAQ:FLXN) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Institutional and Insider Ownership

78.3% of uniQure shares are held by institutional investors. 17.0% of Flexion Therapeutics shares are held by company insiders. Comparatively, 2.8% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Flexion Therapeutics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Flexion Therapeutics and uniQure, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Flexion Therapeutics01913.00
uniQure011113.00

Flexion Therapeutics currently has a consensus price target of $20.4545, suggesting a potential upside of 151.90%. uniQure has a consensus price target of $68.4615, suggesting a potential upside of 102.91%. Given Flexion Therapeutics' higher possible upside, research analysts clearly believe Flexion Therapeutics is more favorable than uniQure.

Valuation and Earnings

This table compares Flexion Therapeutics and uniQure's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flexion Therapeutics$72.96 million5.56$-149,770,000.00($3.93)-2.07
uniQure$7.28 million208.53$-124,200,000.00($3.11)-10.85

uniQure has lower revenue, but higher earnings than Flexion Therapeutics. uniQure is trading at a lower price-to-earnings ratio than Flexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Flexion Therapeutics and uniQure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Flexion Therapeutics-153.90%N/A-53.31%
uniQure-2,738.33%-59.64%-41.47%

Summary

Flexion Therapeutics beats uniQure on 7 of the 13 factors compared between the two stocks.


Flexion Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.58-0.5%$1.16 billion$230,000.00-12.36
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38-8.0%$1.15 billionN/A-8.88News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.54-1.6%$1.14 billionN/A0.00Unusual Options Activity
Lockup Expiration
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$30.78-0.7%$1.14 billionN/A0.00News Coverage
Omeros logo
OMER
Omeros
1.4$18.23-2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81-1.8%$1.09 billion$42.12 million-11.71News Coverage
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50-1.4%$1.08 billionN/A-8.30Analyst Report
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42-7.3%$1.07 billion$120,000.00-3.86News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57-1.3%$1.07 billionN/A-8.82
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16-2.8%$1.07 billion$1.52 million-11.79News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.27-1.9%$1.07 billionN/A-7.00
NKTX
Nkarta
1.8$32.28-1.6%$1.06 billionN/A0.00
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54-0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75-1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00-1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76-1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37-0.2%$958.34 millionN/A-26.27
Annexon logo
ANNX
Annexon
1.9$24.93-0.9%$951.28 millionN/A0.00
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.